Overexpression of Taspase 1 Predicts Poor Prognosis in Patients with Hepatocellular Carcinoma

References

• Llovet JM, Montal R, Sia D, Finn RS. Molecular therapies and precision medicine for hepatocellular carcinoma. Nat Rev Clin Oncol. 2018;15(10):599–616.30061739
   PubMed Web of Science ®Google Scholar
• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.30207593
   PubMed Web of Science ®Google Scholar
• Wang J-H, Zhong X-P, Zhang Y-F, et al. Cezanne predicts progression and adjuvant TACE response in hepatocellular carcinoma. Cell Death Dis. 2017;8(9):e3043–e3043.28880268
   PubMed Web of Science ®Google Scholar
• Llovet J, Zucman-Rossi J, Pikarsky E, et al. Hepatocellular carcinoma. Nature Rev Dis Primers. 2016;2:16018. PubMed PMID: 27158749. doi:10.1038/nrdp.2018.827158749
   PubMed Web of Science ®Google Scholar
• DiStefano JK, Davis B. Diagnostic and prognostic potential of AKR1B10 in human hepatocellular carcinoma. Cancers. 2019;11(4):486. doi:10.3390/cancers11040486
   PubMed Web of Science ®Google Scholar
• López-Otín C, Bond JS. Proteases: multifunctional enzymes in life and disease. J Biol Chem. 2008;283(45):30433–30437. doi:10.1074/jbc.R80003520018650443
   PubMed Web of Science ®Google Scholar
• Verma R, Mohl D, Deshaies RJ. Harnessing the power of proteolysis for targeted protein inactivation. Mol Cell. 2020;77:446–460. doi:10.1016/j.molcel.2020.01.01032004468
   PubMed Web of Science ®Google Scholar
• Hsieh JJ-D, Cheng EH-Y, Korsmeyer SJ. Taspase1: a threonine aspartase required for cleavage of MLL and proper HOX gene expression. Cell. 2003;115(3):293–303. doi:10.1016/S0092-8674(03)00816-X14636557
   PubMed Web of Science ®Google Scholar
• Niizuma H, Cheng EH, Hsieh JJ. Taspase 1: a protease with many biological surprises. Mol cell Oncol. 2015;2(4):e999513. doi:10.1080/23723556.2014.99951327308523
   PubMed Web of Science ®Google Scholar
• Oyama T, Sasagawa S, Takeda S, et al. Cleavage of TFIIA by Taspase1 activates TRF2-specified mammalian male germ cell programs. Dev Cell. 2013;27(2):188–200. doi:10.1016/j.devcel.2013.09.02524176642
   PubMed Web of Science ®Google Scholar
• Capotosti F, Hsieh JJ-D, Herr W. Species selectivity of mixed-lineage leukemia/trithorax and HCF proteolytic maturation pathways. Mol Cell Biol. 2007;27(20):7063–7072. doi:10.1128/MCB.00769-0717698583
   PubMed Web of Science ®Google Scholar
• Chen DY, Liu H, Takeda S, et al. Taspase1 functions as a non-oncogene addiction protease that coordinates cancer cell proliferation and apoptosis. Cancer Res. 2010;70(13):5358–5367.20516119
   PubMed Web of Science ®Google Scholar
• Chen DY, Lee Y, Van Tine BA, et al. A pharmacologic inhibitor of the protease Taspase1 effectively inhibits breast and brain tumor growth. Cancer Res. 2012;72(3):736–746. doi:10.1158/0008-5472.CAN-11-258422166309
   PubMed Web of Science ®Google Scholar
• Takeda S, Chen DY, Westergard TD, et al. Proteolysis of MLL family proteins is essential for taspase1-orchestrated cell cycle progression. Genes Dev. 2006;20(17):2397–2409. doi:10.1101/gad.144940616951254
   PubMed Web of Science ®Google Scholar
• Zhang Y, Du P, Li Y, et al. TASP1 promotes gallbladder cancer cell proliferation and metastasis by Up-regulating FAM49B via PI3K/AKT pathway. Int J Biol Sci. 2020;16(5):739.32071545
   PubMed Web of Science ®Google Scholar
• Niehof M, Borlak J. EPS15R, TASP1, and PRPF3 are novel disease candidate genes targeted by HNF4α splice variants in hepatocellular carcinomas. Gastroenterology. 2008;134(4):1191–1202.18395097
   PubMed Web of Science ®Google Scholar
• Rhodes DR, Kalyana-Sundaram S, Mahavisno V, et al. Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. Neoplasia. 2007;9(2):166. doi:10.1593/neo.0711217356713
   PubMed Web of Science ®Google Scholar
• Lánczky A, Nagy Á, Bottai G, et al. miRpower: a web-tool to validate survival-associated miRNAs utilizing expression data from 2178 breast cancer patients. Breast Cancer Res Treat. 2016;160(3):439–446. doi:10.1007/s10549-016-4013-727744485
   PubMed Web of Science ®Google Scholar
• Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017;45(W1):W98–W102. doi:10.1093/nar/gkx24728407145
   PubMed Web of Science ®Google Scholar
• Chandrashekar DS, Bashel B, Balasubramanya SAH, et al. UALCAN: a portal for facilitating tumor subgroup gene expression and survival analyses. Neoplasia. 2017;19(8):649–658. doi:10.1016/j.neo.2017.05.00228732212
   PubMed Web of Science ®Google Scholar
• Koch A, Jeschke J, Van Criekinge W, van Engeland M, De Meyer T. MEXPRESS update 2019. Nucleic Acids Res. 2019;47(W1):W561–W565.31114869
   PubMed Web of Science ®Google Scholar
• Vasaikar SV, Straub P, Wang J, Zhang B. LinkedOmics: analyzing multi-omics data within and across 32 cancer types. Nucleic Acids Res. 2018;46(D1):D956–D963. doi:10.1093/nar/gkx109029136207
   PubMed Web of Science ®Google Scholar
• Gao J, Aksoy BA, Dogrusoz U, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013;6(269):pl1–pl1.23550210
   PubMed Web of Science ®Google Scholar
• Szklarczyk D, Franceschini A, Wyder S, et al. STRING v10: protein–protein interaction networks, integrated over the tree of life. Nucleic Acids Res. 2015;43(D1):D447–D452.25352553
   PubMed Web of Science ®Google Scholar
• Li T, Fan J, Wang B, et al. TIMER: a web server for comprehensive analysis of tumor-infiltrating immune cells. Cancer Res. 2017;77(21):e108–e110. doi:10.1158/0008-5472.CAN-17-030729092952
   PubMed Web of Science ®Google Scholar
• Ru B, Wong CN, Tong Y, et al. TISIDB: an integrated repository portal for tumor–immune system interactions. Bioinformatics. 2019;35(20):4200–4202.30903160
   PubMed Web of Science ®Google Scholar
• López-Otín C, Overall CM. Protease degradomics: a new challenge for proteomics. Nat Rev Mol Cell Biol. 2002;3(7):509–519.12094217
   PubMed Web of Science ®Google Scholar
• López-Otín C, Matrisian LM. Emerging roles of proteases in tumour suppression. Nat Rev Cancer. 2007;7(10):800–808.17851543
   PubMed Web of Science ®Google Scholar
• Dong Y, Van Tine BA, Oyama T, Wang PI, Cheng EH, Hsieh JJ. Taspase1 cleaves MLL1 to activate cyclin E for HER2/neu breast tumorigenesis. Cell Res. 2014;24(11):1354–1366.25267403
   PubMed Web of Science ®Google Scholar
• Dall’Era MA, McPherson JD, Gao AC, DeVere White RW, Gregg JP, Lara PN Jr. Germline and somatic DNA repair gene alterations in prostate cancer. Cancer. 2020.
   PubMedGoogle Scholar
• Li G, Xu W, Zhang L, et al. Development and validation of a CIMP-associated prognostic model for hepatocellular carcinoma. EBioMedicine. 2019;47:128–141.31492561
   PubMed Web of Science ®Google Scholar
• Zack TI, Schumacher SE, Carter SL, et al. Pan-cancer patterns of somatic copy number alteration. Nat Genet. 2013;45(10):1134–1140.24071852
   PubMed Web of Science ®Google Scholar
• Urrutia E, Chen H, Zhou Z, Zhang NR, Jiang Y. Integrative pipeline for profiling DNA copy number and inferring tumor phylogeny. Bioinformatics. 2018;34(12):2126–2128.29415173
   PubMed Web of Science ®Google Scholar
• Li Y-S, Zou Y, Dai D-Q. MicroRNA-320a suppresses tumor progression by targeting PBX3 in gastric cancer and is downregulated by DNA methylation. World J Gastrointest Oncol. 2019;11(10):842.31662823
   PubMed Web of Science ®Google Scholar
• Zhang C, Zou Y, Dai D-Q. Downregulation of microRNA-27b-3p via aberrant DNA methylation contributes to malignant behavior of gastric cancer cells by targeting GSPT1. Biomed Pharmacother. 2019;119:109417.31539861
   PubMed Web of Science ®Google Scholar
• Sastry NG, Wan X, Huang T, et al. LY6K promotes glioblastoma tumorigenicity via CAV-1–mediated ERK1/2 signaling enhancement. Neuro-Oncology. 2020.
   PubMed Web of Science ®Google Scholar
• Qiu J, Peng B, Tang Y, et al. CpG methylation signature predicts recurrence in early-stage hepatocellular carcinoma: results from a multicenter study. J Clin Oncol. 2017;35(7):734–742. doi:10.1200/JCO.2016.68.215328068175
   PubMed Web of Science ®Google Scholar
• Dietrich P, Wormser L, Fritz V, et al. Molecular crosstalk between Y5 receptor and neuropeptide Y drives liver cancer. J Clin Invest. 2020;130(5):2509–2526. doi:10.1172/JCI13191931999643
   PubMed Web of Science ®Google Scholar
• Caballero-Díaz D, Bertran E, Peñuelas-Haro I, et al. Clathrin switches transforming growth factor-β role to pro-tumorigenic in liver cancer. J Hepatol. 2020;72(1):125–134. doi:10.1016/j.jhep.2019.09.01231562907
   PubMed Web of Science ®Google Scholar
• Kovar H, Bierbaumer L, Radic-Sarikas B. The YAP/TAZ pathway in osteogenesis and bone sarcoma pathogenesis. Cells. 2020;9(4):972. doi:10.3390/cells9040972
   PubMed Web of Science ®Google Scholar
• Yogosawa S, Yoshida K. Tumor suppressive role for kinases phosphorylating p53 in DNA damage-induced apoptosis. Cancer Sci. 2018;109(11):3376–3382. doi:10.1111/cas.1379230191640
   PubMed Web of Science ®Google Scholar
• Karimian A, Ahmadi Y, Yousefi B. Multiple functions of p21 in cell cycle, apoptosis and transcriptional regulation after DNA damage. DNA Repair (Amst). 2016;42:63–71. doi:10.1016/j.dnarep.2016.04.00827156098
   PubMed Web of Science ®Google Scholar
• Ha G-H, Ji J-H, Chae S, et al. Pellino1 regulates reversible ATM activation via NBS1 ubiquitination at DNA double-strand breaks. Nat Commun. 2019;10(1):1–18. doi:10.1038/s41467-019-09641-930602773
   PubMed Web of Science ®Google Scholar
• Seibert M, Krüger M, Watson NA, et al. CDK1-mediated phosphorylation at H2B serine 6 is required for mitotic chromosome segregation. J Cell Biol. 2019;218(4):1164–1181. doi:10.1083/jcb.20180605730765437
   PubMed Web of Science ®Google Scholar
• de Cárcer G, Venkateswaran SV, Salgueiro L, et al. Plk1 overexpression induces chromosomal instability and suppresses tumor development. Nat Commun. 2018;9(1):1–14. doi:10.1038/s41467-018-05429-529317637
   PubMed Web of Science ®Google Scholar
• Halder S, Torrecilla I, Burkhalter MD, et al. SPRTN protease and checkpoint kinase 1 cross-activation loop safeguards DNA replication. Nat Commun. 2019;10(1):1–18. doi:10.1038/s41467-019-11095-y30602773
   PubMed Web of Science ®Google Scholar
• Wang Q, Su L, Liu N, Zhang L, Xu W, Fang H. Cyclin dependent kinase 1 inhibitors: a review of recent progress. Curr Med Chem. 2011;18(13):2025–2043. doi:10.2174/09298671179559011021517772
   PubMed Web of Science ®Google Scholar
• Li L, Huang K, Zhao H, Chen B, Ye Q, Yue J. CDK1-PLK1/SGOL2/ANLN pathway mediating abnormal cell division in cell cycle may be a critical process in hepatocellular carcinoma. Cell Cycle. 2020;1–17. doi:10.1080/15384101.2019.168948231809227
   PubMed Web of Science ®Google Scholar
• Zhang L, Xu J, Yang G, Li H, Guo X. miR-202 inhibits cell proliferation, migration, and invasion by targeting epidermal growth factor receptor in human bladder cancer. Oncol Res Featuring Preclinical Clin Cancer Ther. 2018;26(6):949–957. doi:10.3727/096504018X15149787144385
   Web of Science ®Google Scholar
• Wang G, Fang X, Han M, Wang X, Huang Q. MicroRNA-493-5p promotes apoptosis and suppresses proliferation and invasion in liver cancer cells by targeting VAMP2. Int J Mol Med. 2018;41(3):1740–1748. doi:10.3892/ijmm.2018.335829328362
   PubMed Web of Science ®Google Scholar
• Huang Y-H, Lin Y-H, Chi H-C, et al. Thyroid hormone regulation of miR-21 enhances migration and invasion of hepatoma. Cancer Res. 2013;73(8):2505–2517. doi:10.1158/0008-5472.CAN-12-221823442323
   PubMed Web of Science ®Google Scholar
• Sahraei M, Chaube B, Liu Y, et al. Suppressing miR-21 activity in tumor-associated macrophages promotes an antitumor immune response. J Clin Invest. 2019;129:12.30601137
   PubMed Web of Science ®Google Scholar
• Zhuang D, Liang L, Zhang H, Feng X. MiR-202 suppresses hepatocellular carcinoma progression via down-regulating BCL2 expression. Oncol Res Featuring Preclinical Clin Cancer Ther. 2020;28:399–408. doi:10.3727/096504020X15864296270581
   Web of Science ®Google Scholar
• Ding W, Tan H, Li X, et al. MicroRNA-493 suppresses cell proliferation and invasion by targeting ZFX in human hepatocellular carcinoma. Cancer Biomarkers. 2018;22(3):427–434. doi:10.3233/CBM-17103629758928
   PubMed Web of Science ®Google Scholar
• Wang W-Y, Zhang H-F, Wang L, et al. miR-21 expression predicts prognosis in hepatocellular carcinoma. Clin Res Hepatol Gastroenterol. 2014;38(6):715–719. doi:10.1016/j.clinre.2014.07.00125150373
   PubMed Web of Science ®Google Scholar
• Cao L-Q, Yang X-W, Chen Y-B, Zhang D-W, Jiang X-F, Xue P. Exosomal miR-21 regulates the TETs/PTENp1/PTEN pathway to promote hepatocellular carcinoma growth. Mol Cancer. 2019;18(1):148. doi:10.1186/s12943-019-1075-231656200
   PubMed Web of Science ®Google Scholar
• Xing J, Bhuria V, Bui KC, et al. Haprolid inhibits tumor growth of hepatocellular carcinoma through Rb/E2F and Akt/mTOR inhibition. Cancers. 2020;12(3):615. doi:10.3390/cancers12030615
   PubMed Web of Science ®Google Scholar
• Kent LN, Bae S, Tsai S-Y, et al. Dosage-dependent copy number gains in E2f1 and E2f3 drive hepatocellular carcinoma. J Clin Invest. 2017;127(3):830–842. doi:10.1172/JCI8758328134624
   PubMed Web of Science ®Google Scholar
• Bindea G, Mlecnik B, Tosolini M, et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity. 2013;39(4):782–795. doi:10.1016/j.immuni.2013.10.00324138885
   PubMed Web of Science ®Google Scholar
• Liu X, Wu S, Yang Y, Zhao M, Zhu G, Hou Z. The prognostic landscape of tumor-infiltrating immune cell and immunomodulators in lung cancer. Biomed Pharmacother. 2017;95:55–61. doi:10.1016/j.biopha.2017.08.00328826097
   PubMed Web of Science ®Google Scholar
• Balkwill F. Cancer and the chemokine network. Nat Rev Cancer. 2004;4(7):540–550. doi:10.1038/nrc138815229479
   PubMed Web of Science ®Google Scholar
• Crespo J, Sun H, Welling TH, Tian Z, Zou W. T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment. Curr Opin Immunol. 2013;25(2):214–221. doi:10.1016/j.coi.2012.12.00323298609
   PubMed Web of Science ®Google Scholar
• Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer. 2005;5(4):263–274. doi:10.1038/nrc158615776005
   PubMed Web of Science ®Google Scholar
• Gu Y, Li X, Bi Y, et al. CCL14 is a prognostic biomarker and correlates with immune infiltrates in hepatocellular carcinoma. Aging. 2020;12(1):784. doi:10.18632/aging.10265631927532
   PubMedGoogle Scholar
• Li Q, Shi L, Gui B, et al. Binding of the JmjC demethylase JARID1B to LSD1/NuRD suppresses angiogenesis and metastasis in breast cancer cells by repressing chemokine CCL14. Cancer Res. 2011;71(21):6899–6908. doi:10.1158/0008-5472.CAN-11-152321937684
   PubMed Web of Science ®Google Scholar
• Borch TH, Donia M, Andersen MH, Svane IM. Reorienting the immune system in the treatment of cancer by using anti-PD-1 and anti-PD-L1 antibodies. Drug Discov Today. 2015;20(9):1127–1134. doi:10.1016/j.drudis.2015.07.00326189934
   PubMed Web of Science ®Google Scholar
• Rotte A, Jin J, Lemaire V. Mechanistic overview of immune checkpoints to support the rational design of their combinations in cancer immunotherapy. Ann Oncol. 2018;29(1):71–83. doi:10.1093/annonc/mdx68629069302
   PubMed Web of Science ®Google Scholar